Field Notes #12: Beyond the Breakthrough Headlines
A new US survey records health changes people attribute to five psychoactive drugs. Its small subgroups and different recall windows matter as much as the headlines.
Latest
Field Notes #11: Who Gets Paid for the Root?
Gabon wants a share of the ibogaine boom. New reporting exposes the distance between paying for bark and sharing the value created afterward.
The Alkaloid #31: The Leaf and the Label
Kratom leaf and concentrated 7-OH can share a name on the shelf without sharing a chemical profile. The distinction matters for safety, research and regulation.
The Alkaloid #30: The Jobs Behind the Jar
Before a cannabis jar reaches the counter, someone grows, harvests and cures it. Massachusetts' repeal debate is also about those paychecks, the businesses behind them and the limits of promises about what comes next.
The Alkaloid #29: The Right to Have It. Nowhere Legal to Buy It.
Massachusetts could preserve an adult's right to possess cannabis while closing recreational shops and ending home grows. Who benefits—and what would police be asked to do again?
The Alkaloid #28: The Medicine Needs More Than a Molecule
The FDA is asking who delivers psychedelic care, how patients are protected, and who pays. The practical work extends well beyond the drug.
Field Notes #10: A Room of Their Own
Cannabis-friendly social spaces need more than a place to consume. St. Louis offers a look at the work of hosting.
Field Notes #9: The New Social Drink
THC drinks borrow the rituals of a night out. Familiar packaging does not make the intoxicant familiar.
The Alkaloid #27: From the Parking Lot to the Poster
Cannabis gets an official place in the event program. What two upcoming events promise, and what a small music study can actually tell us.
The Alkaloid #26: The 227 Smells of Cannabis
A new cannabis genetics paper cataloged 227 volatile terpenes across six cultivars. The fun part is what those compounds reveal about flower, genes, and why your nose keeps finding more than a THC label can say.
The Alkaloid #25: The Deadline That Hasn't Moved
Everyone reported that the federal hemp ban slipped to December 11. It hasn't passed the House, and the delay is narrower than the coverage suggests: it turns on whether a molecule is capable of being naturally produced, not on how it was actually made. What that sorts, and what it strands.
The Alkaloid #24: The Same Three Grams
Two clinical trials of lion's mane both gave subjects three grams a day. One of them used ten times more mushroom than the other. Seventeen years of research, seven small trials, and still no agreement on what a dose is. Plus Curaleaf goes hostile on Aurora, and Yale prices federal legalization.
newsletter
The Alkaloid #23: The Question It Was Asking
PsiDeR was built to answer whether the NHS could run a psilocybin trial at all. It could. The 12.92-point depression result everyone reported is a secondary outcome, and the researchers said so plainly. Their press office left that part out. Plus: the Senate blinks on hemp.
newsletter
The Alkaloid #22: The Alarm That Didn't Ring
Past-month cannabis use among Minnesota teens fell from 13% to 5% across twelve years of steadily looser law, and the predicted spike never came. The decline also never reached Native, LGBTQ+ or low-income students, who were three times more likely to use in 2013 and still are today.
newsletter
The Alkaloid #21: The Honest Third
Researchers pooled 28 studies covering 937 CBD products and found just 31.3 percent contained what the label claimed. Topicals came in at 13.8 percent. Plus undisclosed THC, synthetic cannabinoids, heavy metals, and why the number on the box can be wrong in four different ways.
Field Notes
Field Notes #8: The Other Mushroom Boom
While psychedelic mushrooms fight for legal status, their boring cousins quietly became a near-$85 billion wellness industry. What the science on lion's mane and reishi actually shows — and where the marketing gets ahead of it.
Field Notes
Field Notes #7: Five Doors, One Room
Psilocybin, LSD, DMT, mescaline, ayahuasca — five different molecules. A Nature Medicine mega-analysis of 267 people and 500+ brain scans found they all leave the same fingerprint: they don't quiet the brain, they connect it.
newsletter
The Alkaloid #20: The Oldest Trip
Humans have used peyote for 5,700 years, yet mescaline is the psychedelic neuroscience knows least. A new Northeastern brain scan shows the oldest trip has a signature all its own — and Big Pharma just bet up to $3.8B on its molecular cousins.
newsletter
The Alkaloid #19: The Strain That Was a Species
For years, home growers prized a potent magic mushroom called Natal Super Strength. Nobody had ever named it. New DNA work shows it is a separate species, and its family tree pushes the origins of the world's favorite psychedelic mushroom back more than a million years.
newsletter
The Alkaloid #18: The Trip Is Optional
What if the trip was never the point? A new class of compounds promises the brain-rewiring of psychedelics without the hallucination, and the first non-tripping antidepressant is heading for trials you can run from your own couch.
newsletter
The Alkaloid #17: The Munchies, Decoded
Scientists finally caught the munchies in the act. A new study shows cannabis turns up the brain's reward for food, spikes the hunger hormone, and sharpens taste. The same circuit could feed people who can't eat.
newsletter
The Alkaloid #16: The Grandparent Trip
Psychedelic science spent sixty years studying the young. A new UC Berkeley study finally hands the eye mask to people between 60 and 85 — and asks whether an old brain can still change its mind.
Field Notes
Field Notes #6: Two Roads to the Same Molecule
Psilocybin makes a magic mushroom magic. A new study shows two unrelated mushroom groups evolved it separately, by completely different chemical routes that meet only near the finish. Which raises the question decades of human fascination still can't answer: what is psilocybin actually for?
newsletter
The Alkaloid #15: The Factory in the Leaf
A lab in Israel engineered one tobacco plant to make psilocybin, DMT, bufotenin, 5-MeO-DMT, and psilocin at once. The molecules just left the mushroom and the toad behind. What that means for cost, supply, and a drug law written when the drug and its source were the same thing.